Back to search

Article

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) program

2025-11-10

Abstract excerpt

Background Sickle Cell Disease (SCD) is highly prevalent in Nigeria, with severe pain crises being a primary cause of morbidity. Codeine and tramadol are frequently used opioids, but their effectiveness and safety are significantly influenced by CYP2D6 genetic variations. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines exist for opioid therapy based on CYP2D6 phenotypes. There’s a critical n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
83c244cd-dc22-5437-b29b-76e97c3deb79
DOI
10.12688/gatesopenres.16370.1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) programDOI 10.12688/gatesopenres.16370.1
Clinically Actionable Pharmacogenomic Variants for Anticancer Therapy in Nigeria: First Comprehensive Variant Profiling in Underrepresented Nigerian CohortsSemantic proximity
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public healthSemantic proximity
Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts.Semantic proximity
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity
Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision MedicineSemantic proximity
Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.Semantic proximity
Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell DiseaseSemantic proximity
Towards Genomic Medicine: A Tailored Next-Generation Sequencing Panel for Hydroxyurea Pharmacogenomics in TanzaniaSemantic proximity
African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in AfricaSemantic proximity
Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry.Semantic proximity
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.Semantic proximity
Select a neighboring publication to make it the new centre.